AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021

July 22, 2021 GMT

JERSEY CITY, N.J.--(BUSINESS WIRE)--Jul 22, 2021--

Organon (NYSE: OGN) will release its second quarter 2021 financial results on August 12, 2021, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET.

Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.

Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: http://www.directeventreg.com/registration/event/9577397. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including dial-in information and a unique passcode and registrant ID. Pre-registration will allow participants to bypass an operator and be placed directly into the call.

ADVERTISEMENT

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development, including business development like recently acquired Alydia Health, a medical device company focused on postpartum hemorrhage. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.

ADVERTISEMENT

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210722005370/en/

CONTACT: Media Contacts:

Karissa Peer

(614) 314-8094

Kate Vossen

(732) 675-8448

Investor Contacts:

Jennifer Halchak

(201) 275-2711

Edward Barger

(267) 614-4669

KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Organon & Co.

Copyright Business Wire 2021.

PUB: 07/22/2021 08:30 AM/DISC: 07/22/2021 08:32 AM

http://www.businesswire.com/news/home/20210722005370/en